Want to see ARWR full AI Analyst Report?
ARWR Stock Chart & Stats
$69.51
$0.33(1.68%)
At close: 4:00 PM EST
$69.51
$0.33(1.68%)
Day’s Range― - ―
52-Week Range$14.30 - $87.83
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.26M
Market Cap
$11.83B
Enterprise Value$12.60B
Total Cash (Recent Filing)$1.78B
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 06, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding140,857,030
10 Day Avg. Volume3,541,508
30 Day Avg. Volume2,264,941
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue20.26
Enterprise Value/Gross Profit20.26
Enterprise Value/Ebitda-93.70
Forecast
1Y Price Target
$89.25Price Target Upside28.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.12
Revenue Forecast (FY)$448.67M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumSustained, accelerating prescription growth indicates early physician adoption, payer access and patient demand that can compound over time. Durable adoption among APOC3‑naive patients and some switchers supports a credible commercial foothold and scale potential as international approvals and launches progress.
Broad, Innovative PipelineA diversified pipeline across multiple tissues and modalities reduces single‑asset binary risk and increases long‑term upside from multiple potential approvals. Proprietary RNAi platform and novel constructs (dual siRNA, CNS delivery) create durable technical differentiation and multiple future value inflection points.
Strengthened Balance Sheet And PartnershipsA materially larger cash position and sizable non‑dilutive/partner payments extend runway for registrational trials and commercialization investments. The capital raise and licensing deals (milestones/royalties) lower near‑term funding risk and allow strategic execution without immediate reliance on dilutive equity.
Bears Say
Elevated LeverageHigher leverage reduces financial flexibility and increases refinancing and covenant risk if clinical or commercial setbacks occur. With sizeable R&D and SG&A spend and volatile revenues, elevated debt can amplify downside pressure on cash flow and constrain strategic options over the medium term.
Inconsistent Cash GenerationVolatile operating cash flow undermines self‑funding of trials and commercialization. Reliance on sporadic partner payments and financings increases execution risk, potentially forcing dilutive capital raises or milestone concessions that could impair long‑term returns if organic cash generation does not stabilize.
Nascent Product Sales And Limited Commercial VisibilityWith commercial sales still immaterial and company withholding gross‑to‑net/unit detail, realized economics and margin sustainability remain unproven. This limits visibility on durable revenue growth and payer reimbursement dynamics, increasing risk that strong launch metrics may not translate to sustained, profitable sales.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals, Inc.’s price range in the past 12 months?
Arrowhead Pharmaceuticals, Inc. lowest stock price was $14.30 and its highest was $87.83 in the past 12 months.
What is Arrowhead Pharmaceuticals, Inc.’s market cap?
Arrowhead Pharmaceuticals, Inc.’s market cap is $11.83B.
When is Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date?
Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Arrowhead Pharmaceuticals, Inc.’s earnings last quarter?
Arrowhead Pharmaceuticals, Inc. released its earnings results on May 07, 2026. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$1.095 by $0.165.
Is Arrowhead Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals, Inc. pay dividends?
Arrowhead Pharmaceuticals, Inc. does not currently pay dividends.
What is Arrowhead Pharmaceuticals, Inc.’s EPS estimate?
Arrowhead Pharmaceuticals, Inc.’s EPS estimate is -1.22.
How many shares outstanding does Arrowhead Pharmaceuticals, Inc. have?
Arrowhead Pharmaceuticals, Inc. has 140,857,030 shares outstanding.
What happened to Arrowhead Pharmaceuticals, Inc.’s price movement after its last earnings report?
Arrowhead Pharmaceuticals, Inc. reported an EPS of -$0.93 in its last earnings report, beating expectations of -$1.095. Following the earnings report the stock price went down -6.748%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ARWR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.25 (28.40% Upside)
$89.25 (28.40% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
344.91%
12-Months-Change
Fundamentals
Return on Equity
-55.45%
Trailing 12-Months
Asset Growth
44.15%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
ARWR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented tone: the REDEMPLO launch is exceeding early expectations with accelerating prescriptions, the company has a broad and innovative clinical pipeline with several near-term catalyst readouts, and a materially strengthened balance sheet provides capital flexibility. Counterbalancing this are the early-stage/commercial sales (net product sales ~ $1M), a quarterly net loss driven by elevated R&D/SG&A spend and dependence on upcoming pivotal readouts for label expansion and commercial scale. On balance, the positives (strong launch momentum, compelling efficacy data to date, global approvals, and significant funding) outweigh the near-term financial and clinical risks.View all ARWR earnings summariesARWR Stock 12 Month Forecast
Average Price Target
$89.25
▲(28.40% Upside)
Technical Analysis
Ownership Overview
3.66% Insiders
19.74% Mutual Funds
0.18% Other Institutional Investors
50.60% Public Companies and
Individual Investors